Comprehensive bioinformatics analysis identified HMGB3 as a promising immunotherapy target for glioblastoma multiforme.

IF 2.8 4区医学 Q3 ENDOCRINOLOGY & METABOLISM

Discover. Oncology Pub Date : 2025-04-07 DOI:10.1007/s12672-025-02235-6

Libin Wang, Peizhi Xu, Xinglong Li, Qinghua Zhang

{"title":"Comprehensive bioinformatics analysis identified HMGB3 as a promising immunotherapy target for glioblastoma multiforme.","authors":"Libin Wang, Peizhi Xu, Xinglong Li, Qinghua Zhang","doi":"10.1007/s12672-025-02235-6","DOIUrl":null,"url":null,"abstract":"Objective: Glioblastoma multiforme (GBM) presents significant therapeutic challenges due to its heterogeneous tumorigenicity, drug resistance, and immunosuppression. Although several molecular markers have been developed, there still lack of sensitive molecular for accurately detection. Studying the mechanisms underlying the development of GBM and finding relevant prognostic biomarkers remains crucial.Methods: Single-cell RNA sequencing, bulk RNA-seq, and cancer immune cycle activities of GBM were used to assess the expression of different molecular related to GBM. Bioinformatics analyses were carried to evaluate the functional of the high mobility group protein B3 (HMGB3) in GBM.Results: HMGB3 was highly expressed in GBM tissues and influenced the interpatient and intratumoral transcriptomic heterogeneity as well as immunosuppression in GBM. HMGB3 also contributes to a no inflamed tumor microenvironment (TME) and has an inhibitory effect on tumor-associated immune cell infiltration. Besides, HMGB3 participated GBM chemotherapeutic sensitivity and negative correlation with 140 medicines.Conclusion: HMGB3 as a heterogeneous and immunosuppressive molecule in the GBM TME, making it a potential target for precision therapy for GBM.","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"478"},"PeriodicalIF":2.8000,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Discover. Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12672-025-02235-6","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Glioblastoma multiforme (GBM) presents significant therapeutic challenges due to its heterogeneous tumorigenicity, drug resistance, and immunosuppression. Although several molecular markers have been developed, there still lack of sensitive molecular for accurately detection. Studying the mechanisms underlying the development of GBM and finding relevant prognostic biomarkers remains crucial.

Methods: Single-cell RNA sequencing, bulk RNA-seq, and cancer immune cycle activities of GBM were used to assess the expression of different molecular related to GBM. Bioinformatics analyses were carried to evaluate the functional of the high mobility group protein B3 (HMGB3) in GBM.

Results: HMGB3 was highly expressed in GBM tissues and influenced the interpatient and intratumoral transcriptomic heterogeneity as well as immunosuppression in GBM. HMGB3 also contributes to a no inflamed tumor microenvironment (TME) and has an inhibitory effect on tumor-associated immune cell infiltration. Besides, HMGB3 participated GBM chemotherapeutic sensitivity and negative correlation with 140 medicines.

Conclusion: HMGB3 as a heterogeneous and immunosuppressive molecule in the GBM TME, making it a potential target for precision therapy for GBM.

查看原文本刊更多论文

综合生物信息学分析发现HMGB3是多形性胶质母细胞瘤的一个有前途的免疫治疗靶点。

目的：多形性胶质母细胞瘤（GBM）因其异质性致瘤性、耐药性和免疫抑制性而面临着重大的治疗挑战。虽然已经开发了几种分子标记，但仍缺乏准确检测的灵敏分子。研究GBM发展的潜在机制和寻找相关的预后生物标志物仍然至关重要。方法：采用单细胞RNA测序、bulk RNA-seq和肿瘤免疫周期活性检测GBM相关分子的表达。采用生物信息学方法评价高迁移率组蛋白B3 （HMGB3）在GBM中的功能。结果：HMGB3在GBM组织中高表达，影响了GBM患者间和瘤内转录组异质性及免疫抑制。HMGB3还有助于无炎症肿瘤微环境（TME），并对肿瘤相关免疫细胞浸润具有抑制作用。HMGB3参与GBM化疗敏感性，与140种药物呈负相关。结论：HMGB3在GBM TME中具有异质性和免疫抑制作用，是GBM精准治疗的潜在靶点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊